Benefits
Endothelial function and blood vessel dilation
In a 3-week crossover trial in 24 adults with metabolic syndrome, 500 mg a day of hesperidin improved artery dilation versus placebo. In healthy overweight men, about 292 mg a day improved small-vessel reactivity after a dose but not when fasting. Two 6-week trials, at 450 and 210 mg a day, found no change in artery dilation.
Blood pressure support
In healthy overweight men, 4 weeks of hesperidin capsules lowered diastolic blood pressure versus placebo capsules with the same control drink. In 159 adults with mildly raised blood pressure, orange juice with natural or added hesperidin lowered systolic pressure versus a control drink over 12 weeks, but the two juices did not differ. A 6-week 450 mg trial saw only a non-significant trend, and pooled analyses disagree.
Cholesterol and triglyceride markers
In 204 adults with moderately raised cholesterol, 800 mg a day of pure hesperidin for 4 weeks did not change total, LDL or HDL cholesterol or triglycerides versus placebo. A pooled analysis of 10 trials also found no lipid effect, while a later one reported lower total and LDL cholesterol and triglycerides overall, with the clearest effects in trials longer than 12 weeks.
Circulating inflammatory markers
In the 24-person metabolic syndrome trial, 500 mg a day lowered C-reactive protein, serum amyloid A and soluble E-selectin versus placebo. In a 450 mg trial, blood-vessel adhesion molecules showed only a non-significant downward trend. A pooled analysis reported lower TNF-alpha but no change in C-reactive protein.
Leg comfort in MPFF studies (a diosmin-based flavonoid product)
In 7 placebo-controlled trials of adults with chronic venous disease, MPFF, a product that is 90% micronized diosmin and 10% other flavonoids expressed as hesperidin, eased leg pain, heaviness, feeling of swelling and cramps. A review of vein-tone products as a class found slightly less leg swelling and little or no change in quality of life. Neither shows what hesperidin alone does.
Mechanism of action
Nitric oxide release in blood-vessel cells
In cultured bovine endothelial cells, hesperetin, the aglycone of hesperidin, activated endothelial nitric oxide synthase and raised nitric oxide production. It also reduced monocyte adhesion and VCAM-1 expression after an inflammatory signal. These are cell findings, not human results.
Changes in white blood cell gene activity
In 10 men, 4 weeks of hesperidin capsules changed the activity of 1,819 genes in white blood cells, many tied to cell adhesion, migration and lipid transport. The authors read this as a less inflammatory profile; it is a marker study, not a clinical outcome.
Absorption as hesperetin metabolites
After hesperidin or orange juice, what shows up in blood is measured as hesperetin metabolites. In one crossover trial, exposure was similar from juice and from a hesperidin drink, and it varied widely from person to person.
Clinical trials
Randomized, placebo-controlled, double-blind crossover trial; 500 mg hesperidin once a day for 3 weeks per period. The paper also includes cell experiments. (Rizza et al. 2011, J Clin Endocrinol Metab)
24 adults with metabolic syndrome.
Brachial artery flow-mediated dilation was higher after hesperidin than after placebo (10.26% vs 7.78%, P = 0.02). High-sensitivity C-reactive protein, serum amyloid A and soluble E-selectin were lower. The authors describe the trial as exploratory.
Randomized, controlled crossover trial with three 4-week periods: orange juice, a control drink plus hesperidin capsules, or a control drink plus placebo capsules; registered NCT00983086. The companion paper gives the hesperidin dose as 292 mg a day, describes the control drink as sugar-matched (isocaloric) to the juice and the two capsule arms as double-blind, and reports that the work was supported by the Florida Department of Citrus, which supplied the orange juice. (Morand et al. 2011, Am J Clin Nutr)
24 healthy, moderately overweight men aged 50 to 65.
Diastolic blood pressure was lower after 4 weeks of hesperidin or orange juice than after the placebo drink (P = 0.02). Fasting microvascular endothelial reactivity did not change; reactivity measured after a dose, at peak blood hesperetin, improved versus placebo (P < 0.05).
Randomized, double-blind, placebo-controlled parallel trial; 450 mg a day of hesperidin 2S for 6 weeks, with a high-fat meal test; registered NCT02228291. Two authors were affiliated with BioActor BV. (Salden et al. 2016, Am J Clin Nutr)
68 overweight or obese adults.
No significant change in fasting or post-meal flow-mediated dilation, the primary outcome, versus placebo. Adhesion molecules and systolic and diastolic blood pressure showed non-significant downward trends. An exploratory subgroup with better baseline vessel function did better; results were not adjusted for multiple testing.
Randomized, double-blind, controlled three-period crossover trial; 6 weeks each of 330 mL orange juice, a control drink, or a control drink with 210 mg hesperidin a day. Registered as NCT04731987 (HESPER-HEALTH), which lists the European Fruit Juice Association (AIJN) as a collaborator; the published protocol reports juice industry funding. (Gilcher et al. 2026, Food Funct)
37 centrally overweight men who completed the trial.
Neither orange juice nor hesperidin significantly changed fasting or post-meal flow-mediated dilation, the primary outcome, or other vascular, metabolic or body measures versus control. Blood hesperetin metabolites were similar after juice and hesperidin, with wide person-to-person variation.
Randomized, placebo-controlled, parallel trial with three arms (800 mg hesperidin, 500 mg naringin, or placebo capsules at mealtime) for 4 weeks after a 4-week run-in. The first author was affiliated with Unilever R&D. (Demonty et al. 2010, J Nutr)
204 healthy men and women with moderately raised total cholesterol (5.0 to 8.0 mmol/L); 194 completed.
Hesperidin did not change total or LDL cholesterol versus placebo (adjusted LDL 3.99 vs 4.00 mmol/L). HDL cholesterol and triglycerides were also unchanged.
Randomized, parallel, double-blind, placebo-controlled trial (Citrus study, registered NCT02479568); 500 mL a day of control drink, orange juice, or hesperidin-enriched orange juice for 12 weeks. Funded by the Florida Department of Citrus, which supplied the drinks; Ferrer HealthTech donated the micronized hesperidin. (Valls et al. 2021, Eur J Nutr)
159 adults with pre- or stage 1 hypertension.
Systolic blood pressure fell more than with the control drink after both orange juice (345 mg hesperidin a day) and hesperidin-enriched juice (600 mg a day), with a dose-related trend by hesperidin content; the two juices did not differ significantly from each other, so the juice itself may account for part of the effect. Diastolic pressure fell similarly in all three groups, and the pulse pressure trend was not significant at week 12. Both juices lowered homocysteine versus the control drink. In single-dose tests, only enriched juice lowered systolic and pulse pressure. No adverse events were reported; 129 of 159 completed.